Astrana Health (NASDAQ:ASTH) Announces Quarterly Earnings Results

Astrana Health (NASDAQ:ASTH) announced its quarterly earnings results on Thursday. The company reported $0.74 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.45, FiscalAI reports. Astrana Health had a net margin of 0.86% and a return on equity of 9.31%. The firm had revenue of $965.10 million for the quarter, compared to analyst estimates of $949.21 million. During the same quarter in the previous year, the firm posted $0.42 earnings per share. The business’s revenue was up 55.6% on a year-over-year basis.

Here are the key takeaways from Astrana Health’s conference call:

• Astrana reported a strong Q1 — $965.1M revenue (+56% YoY), adjusted EBITDA of $66.3M (+82% YoY), adjusted EPS of $0.74, free cash flow of $64.1M, and accelerated deleveraging to ~2.3x pro forma with a target of ≤2.0x by year-end.
• Management highlighted its AI-enabled, payer-agnostic operating system, saying embedded AI agents are already improving outcomes and operations (24% higher gap-closure, 30% higher annual wellness completion, and much faster claims payment) and that benefits should compound over time.
• The business now serves ~1.55M members in value-based arrangements, with ~80% of Care Partners revenue and ~40% of owned membership in full-risk contracts; new full-risk cohorts are tracking to underwriting but Medicaid and Exchange enrollment trends were mixed.
• Prospect integration is on track — gross provider retention >99%, synergies tracking toward the high end of the $12–15M annual target, and Prospect is performing ahead toward ~$80M annualized adjusted EBITDA.
• The company reaffirmed 2026 guidance (revenue $3.8–4.1B, adjusted EBITDA $250–280M, FCF $105–132.5M), gave Q2 targets, and cited the 2027 Medicare Advantage rate notice and its encounter-based approach as structural regulatory tailwinds.

Astrana Health Stock Up 8.9%

ASTH traded up $3.22 during trading on Friday, reaching $39.30. 929,945 shares of the stock were exchanged, compared to its average volume of 474,463. The stock has a market cap of $2.19 billion, a P/E ratio of 24.38 and a beta of 0.98. Astrana Health has a twelve month low of $18.08 and a twelve month high of $39.90. The stock’s 50 day moving average price is $27.38 and its two-hundred day moving average price is $25.67. The company has a debt-to-equity ratio of 1.25, a quick ratio of 1.40 and a current ratio of 1.40.

Analyst Ratings Changes

ASTH has been the topic of a number of recent research reports. BTIG Research lifted their price objective on shares of Astrana Health from $40.00 to $50.00 and gave the company a “buy” rating in a report on Friday. Robert W. Baird set a $45.00 price objective on shares of Astrana Health in a report on Friday. Needham & Company LLC lifted their price objective on shares of Astrana Health from $30.00 to $41.00 and gave the company a “buy” rating in a report on Friday. Truist Financial lifted their price objective on shares of Astrana Health from $37.00 to $38.00 and gave the company a “buy” rating in a report on Friday, March 13th. Finally, Weiss Ratings upgraded shares of Astrana Health from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, April 29th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $38.86.

Key Astrana Health News

Here are the key news stories impacting Astrana Health this week:

• Positive Sentiment: Astrana Health beat first-quarter sales expectations, reporting revenue of $965.1 million versus the $949.2 million consensus, while EPS came in at $0.74, well above the $0.29 estimate. Revenue also rose 55.6% year over year, signaling strong operating momentum. Article title
• Positive Sentiment: The company’s full-year 2026 revenue guidance of $3.8 billion to $4.1 billion was issued near Wall Street expectations, which can support confidence that growth remains intact. Article title
• Positive Sentiment: Needham & Company raised its price target on ASTH to $41 from $30 and kept a buy rating, while BTIG Research lifted its target to $50 from $40 and also reiterated a buy rating. Those moves suggest analysts see more upside after the earnings beat.
• Neutral Sentiment: Investors are also digesting the earnings call transcript and presentation, which may provide additional detail on margins, guidance, and the company’s growth strategy.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors have recently added to or reduced their stakes in ASTH. Royal Bank of Canada increased its holdings in Astrana Health by 6.5% during the first quarter. Royal Bank of Canada now owns 278,619 shares of the company’s stock worth $8,640,000 after buying an additional 17,028 shares during the last quarter. AQR Capital Management LLC acquired a new position in shares of Astrana Health in the first quarter valued at $933,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Astrana Health by 5.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock valued at $799,000 after purchasing an additional 1,263 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in shares of Astrana Health by 4,365.2% in the first quarter. Jones Financial Companies Lllp now owns 11,163 shares of the company’s stock valued at $346,000 after purchasing an additional 10,913 shares during the last quarter. Finally, Intech Investment Management LLC increased its holdings in shares of Astrana Health by 5.8% in the first quarter. Intech Investment Management LLC now owns 44,586 shares of the company’s stock valued at $1,383,000 after purchasing an additional 2,462 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.